Feasibility study of Pre-operative FOLFIRI3 plus cetuximab for KRAS wild type resectable advanced colorectal cancer (mCRC).

ABSTRACT: Interventions: Pre-operative chemotherapy(FOLFIRI3 plusCetuximab)4cycles =>To evaluate effect =>Surgical resection or Continued chemotherapy =>Surgical resection. *FOLFIRI3 plus Cetuximab Cetuximab500 mg/m2/day1/q2w CPT-11 100 mg/m2/day1,3/q2w I-LV 200 mg/m2/day1/q2w 5-FU/infusional 2400 mg/m2/46hr/q2w Primary outcome(s): Treatment completion rate Study Design: Single arm Non-randomized

DISEASE(S): Resectable Advanced Colorectal Cancer

PROVIDER: 2625026 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR